Method for producing a direct compression vehicle for tabletting which involves admixing a crystalline sugar with a maltodextrin and spraying the admixture with an aqueous solution of a maltodextrin. The resulting vehicle may be combined with a pharmaceutically active ingredient wherein the pharmaceutically active ingredient may be present in an amount of up to 80% of the weight of the vehicle. The resulting pharmaceutical composition can be compressed into a tablet having a Strong Cobb Hardness Unit (S.C.H.U.) value of at least about 6.

25 Claims, No Drawings
DIRECT COMPRESSION TABLETTING COMPOSITION AND PHARMACEUTICAL TABLETS PRODUCED THEREFROM

BACKGROUND OF THE INVENTION

1. Field of the Invention:

This invention relates to direct compression tabletting compositions and the pharmaceutical tablets produced therefrom. More particularly, this invention relates to an improved direct compression tabletting composition prepared from a uniquely granulated mixture of a crystalline sugar such as dextrose monohydrate, and a maltodextrin having a measurable dextrose equivalent value not substantially above about 20. The improved direct compression tabletting compositions are capable of being directly compressed into commercially acceptable and hard tablets with large amounts of a variety of active materials. The new direct compression tablets can be used as the sole binder disintegrant without the aid of other adjuvants ordinarily used for this purpose.

2. Description of the Prior Art:

The compressed tablet is the most popular unit dosage form for medicinal substances. The tablet as a dosage form can be traced to well over 1,000 years ago when a procedure for molding solid forms containing medicinal ingredients was recorded. As a result of the introduction of new carriers and compression vehicles, tablets are replacing all forms of pills, powders and capsules. Accordingly, tablets presently represent the largest production volume of all pharmaceuticals.

The reason for the widespread use of tablets is apparent, since tablets enable: (1) administration of medication in an accurate dose, (2) fast and accurate dispensing with less chance of error and contamination, (3) ease of administration, (4) administration in a form in which the time and area of contact between the active ingredient and the taste buds is reduced, thus obviating the physiological problems associated with the oral administration of drugs that possess a bitter taste and, in the case of coated tablets, with drugs that possess a disagreeable odor, (5) release of drugs at specific locations in the gastrointestinal tract to: (a) prevent degradation of drugs sensitive to the low pH environment in the stomach, (b) prevent release of drugs that irritate the gastric mucosa in the stomach, (c) facilitate local action or preferential absorption at specific sites in the tract, (6) enhance stability by effecting a marked reduction in the surface of the drug exposed to the environment, (7) rapid production, and (8) economy and ease in storage, packaging and shipping.

It is well-known that in order to form a tablet of a given material, the material must possess fluidity and compressibility. It is essential that the material must flow uniformly from the hopper to the dies of the tablet press. Any defective flow of the material will effect the weight of the tablets, content uniformity, disintegration time, hardness, friability, and also the bioavailability of the active ingredient.

There are currently three basic methods for tabletting. They are the wet granulation method, the dry granulation method, and the direct compression method. The direct compression method is by far the desired method from the standpoint of processing procedures, equipment and materials. However, only a very limited number of pharmaceutically used substances possess enough cohesive strength and flowability to allow direct compression without preliminary treatment. Also, aspirin, phenothaline, chlorohydrate can be directly compressed.

It has been stated that the ideal material to compress would be composed of crystals which, at the moment of compression, behaved like clay rather than rubber. The crystals should be such that on release of pressure they should not rebound into their original shape. Generally, most materials possess both plastic and elastic deformation properties. Therefore, most materials are not suitable for direct compression without previous granulation.

It has been estimated that about 20% of the materials used for tabletting in the pharmaceutical field may be compressed directly. In order to use this method to a considerable extent, many more materials should be modified by treatment or by use of additives. Modification may be undertaken, either by treating the material in some special way during earlier stages of preparation, or by adding a binder or excipient material which will surround the active ingredient and form an easily compressible carrier.

An ideal direct compression vehicle should possess the following properties: (1) low elastic modules, (2) high dislocation density, (3) inert, non-potent and non-toxic, (4) high degree of plastic deformation, (5) colorless, odorless, tasteless or without disagreeable taste, (6) free-flowing, (7) compatible with active ingredients and common additives like lubricants, colors, etc., (8) non-hygroscopic, or relatively low order of hygroscopicity, (9) fast disintegration properties, or should not delay the bioavailability of the drug, (10) limited range of particle size distribution, (11) stable effects of aging, and (12) reworkable and should possess high carrying capacity for active medicinal agents.

There are currently several available direct compression vehicles. They include spray-dried lactose; anhydrous lactose; microcrystalline cellulose; dicalcium phosphate dehydrate, unmilled; Cellutab; spray-congealed mannitol; Emcompress; Magnapul; Frodex; Di Pac; and Royal-T.

Microcrystalline cellulose is a natural cellulose in a specially processed form which makes it digestible. It normally produces good tablets with fast disintegration and drug release properties. It has been found to give better results if stored in a dry condition before use — exposure to a slightly humid atmosphere makes it compress less easily. It is quite fluffy by nature.

Spray-dried lactose has a heavy appearance when poured and is spherical in shape. It cannot be reworked, as the spherical shape is lost when ground. It has been disclosed that spray-dried lactose with 5-10% maize starch as a disintegrant and 0.5% magnesium stearate as a lubricant forms a useful direct compression base. However, it has the tendency to get brown in the presence of moisture, amines, phosphates, lactates and acetates. Borates and the stearate lubricants tend to retard the browning.

Dicalcium phosphate dehydrate has good flow and compressibility properties. The tablets from dicalcium phosphate are also easily embossed. The increased flow is believed to be due to its high density. It cannot be reworked. Due to its alkaline pH, stability of ingredients like Vitamin C or aspirin may be effected.
The vehicle mannitol, absorbs heat from the surroundings when going into solution, and results in good “mouth feel.” Thus, it is commonly used in chewable tablets. It has been reported that a change in the compression characteristics of mannitol occurs when spray-congealing the product.

The vehicle known in the art as Cellutta is a spray-dried dextrose product. It has excellent flow characteristics. It is relatively coarse compared to other vehicles and contains approximately 8% moisture.

The product known in the art as Encompass is essentially a blend of dicalcium phosphate dehydrate, unmilled; starch; Avacil; and magnesium stearate. It is free-flowing, self-lubricating and possesses good compression characteristics.

The vehicle known in the art as Royal-T is essentially an agglomerated mixture of a crystalline sugar such as dextrose and a maltodextrin such as Mor-Rex Code 1918. The preparation of this bold and new pioneering discovery in the direct compression vehicle art is described in British Pat. No. 1,286,275, published Aug. 23, 1972 which generally corresponds to pending U.S. application Ser. No. 485,480, filed July 3, 1974, which is a continuation-in-part of abandoned U.S. application Ser. No. 254,552, filed May 18, 1972, which in turn is a continuation-in-part of abandoned U.S. application Ser. No. 141,030, filed May 6, 1971, and which in turn is a continuation-in-part of abandoned U.S. application Ser. No. 767,520, filed Oct. 14, 1968.

The vehicle known in the art as Di Pac is also a mixture of a crystalline sugar and a maltodextrin. The preparation of this product is generally described in the aforesaid British patent and, more specifically disclosed in U.S. Pat. No. 3,642,535, granted Feb. 15, 1972.

Although the direct compression method for preparing tablets is by far the method of choice by virtue of its simplicity, this method has several limitations which have hampered its use in the tabletting industry. These limitations include: (1) differences in the particle size, and bulk density between the diluent and the active ingredient may lead to stratification and variation in drug content of tablets, (2) unless the drug itself is easily compressible, the amount present is limited to a maximum of 25% of the tablet weight (Of course, the amount of vehicle and the weight of the tablet may be increased to reduce the percentage of active ingredient. Then there arises a question of economics and size of the tablet, a question that may be resolved only by wet granulation.), (3) the drug may interact with the vehicle, such as amine compounds do with spray-dried lactose, and (4) static charges which may develop on the drug during combination and mixing may prevent uniform distribution.

In light of the limitations mentioned hereinabove, the great percentage of tabletting operations, therefore, have been forced to resort to other formulation techniques such as the wet and dry granulation methods. Thus, there is a continued search for an improved direct compression tabletting composition capable of being employed as a binder in the preparation of tablets by direct compression which are rapidly disintegrative, resistant to breakage and crumbling and compatible with the active material incorporated therein which forms the basis of the composition’s utility.

**SUMMARY OF THE INVENTION**

The present invention relates to an improved direct compression tabletting composition prepared from a uniquely granulated mixture of a crystalline sugar and a maltodextrin having a measurable dextrose equivalent value not substantially above about 20. The direct compression compositions of this invention are prepared by admixing a crystalline sugar with from about 10 to about 50% by weight of a maltodextrin having a measurable dextrose equivalent value not substantially above about 20 to form a uniform admixture and thereafter concurrently agitating and spraying said admixture with an aqueous solution containing dissolved therein the aforesaid maltodextrin having a measurable dextrose equivalent value not substantially above about 20, said aqueous solution of dissolved maltodextrin being present in an amount sufficient to provide a damp mass of said uniform admixture and to cause binding and granulation of said uniform admixture. The granulated mixture is thereafter dried to a moisture content of less than about 10% by weight.

The preferred direct compression compositions of this invention will contain from about 15% to about 35% by weight of said maltodextrin, preferably from about 20-30% by weight of said maltodextrin. The preferred crystalline sugar utilized includes dextrose monohydrate.

It has been found that when a crystalline sugar such as dextrose monohydrate is granulated with at least about 15% by weight of a maltodextrin having a measurable dextrose equivalent value not substantially above 20, the composition has an exceptionally high carrying capacity for a large variety of pharmaceutically active compounds. This result is quite unexpected, inasmuch as the compositions described in British Pat. No. 1,286,275 have a relatively low carrying capacity for most pharmaceutically active compounds. Thus, the compositions of this invention provide a direct compression vehicle which can be directly compressed into commercially acceptable and hard tablets with large amounts of a variety of active materials and can be used as the sole binder disintegrant without the aid of other adjuvants ordinarily used for this purpose.

**DESCRIPTION OF THE PREFERRED EMBODIMENTS**

The crystalline sugars employed in the practice of the present invention include any type of crystalline sugar product, examples of which include dextrose, sucrose, lactose and blends thereof. Many of these crystalline sugars are well-known in the art and are conventional articles of commerce sold under various trade names. Such sugars are generally produced and crystallized by conventional techniques. The preferred crystalline sugar employed in the practice of the present invention is dextrose, either in its monohydrate, anhydrous, or dehydrated form. Dextrose monohydrate is particularly preferred as the crystalline sugar to be utilized in the practice of the invention.

The maltodextrins having a measurable dextrose equivalent value not substantially above about 20 utilized in the practice of the present invention represent a known class of materials. The maltodextrins are also known as hydrolyzed cereal solids and such materials are commercially available under the tradenames Mor-
In the above equation, an equal weight of each of dextrose and the hydrolysate material is involved. The term dextrose equivalent value of a starch hydrolysate is a common expression in the art for describing the total reducing sugars content of a material calculated as dextrose and expressed as percent, dry basis.

An essential aspect of the invention comprises admixing (e.g., by spraying or by any other convenient means) an aqueous solution containing from about 5 to about 60 weight/volume percent of the above-described maltodextrin with a uniform mixture of a crystalline sugar and 10 to about 50% by weight of the above-described maltodextrin. The admixing of the aqueous solution of the maltodextrin should be conducted while the uniform mixture of the crystalline sugar and the maltodextrin is being agitated to achieve uniform and homogeneous contact of the crystalline sugar particles and the maltodextrin with the aqueous solution containing the maltodextrin. Preferably, the aqueous solution will contain from about 10 to about 30% weight/volume of the maltodextrin.

The solution containing the maltodextrin is preferably admixed with the uniform mixture of the crystalline sugar and maltodextrin at ambient temperatures and pressures. Slight deviations may be imposed, provided that such conditions do not adversely affect the compositions.

The amount of the solution containing the maltodextrin utilized may vary, depending on the characteristics of the crystalline sugar, the amount of moisture in the homogeneous mixture of the crystalline sugar and/or the maltodextrin, etc. Generally, the amount of the aqueous solution containing the maltodextrin utilized will be an amount such that its admixture with all of the materials provides a thoroughly admixed damp mass. Such amounts will generally be in the range of from about 20 ml. to about 100 ml. of the aqueous solution per one kilogram (kg.) of the uniform mixture of the crystalline sugar and the maltodextrin. A suitable “damp mass” can be obtained under ordinary conditions utilizing from about 40 ml. to about 60 ml. of the aqueous solution per one kilogram (kg.) of the uniform mixture.

After the aqueous solution containing the maltodextrin is added to the uniform mixture of the crystalline sugar and the maltodextrin, the entire admixture is thoroughly mixed to cause granulation. The granulated product is thereafter dried to a moisture content of less than about 10% by weight, preferably less than about 5% by weight moisture. The dried granulated product may be screened to provide a more homogeneous screen size. The final dried and screened product can be used “as is” as a direct compression tabletting composition whereupon it can simply be admixed with the desired active material and directly compressed into tablets.

The crystalline sugar hereinabove described may be admixed in either dry or wet form with the maltodextrin. Preferably, the crystalline sugar, e.g., dextrose monohydrate, is employed in its centrifuged cake form following crystallization, which cake has been washed and centrifuged so that the water content in the cake (excluding water of hydration, which, if present, comprises 1–16% of the cake weight) will be sufficient to provide the necessary amount of water to initially granulate the crystalline sugar with the maltodextrin. In this respect, the amount of water necessary to initially granu-
ulate the above-described composition of this invention, excluding water of hydration, is preferably from 1-8% by weight of the total composition. The initially granulated admixture may be dried, providing the amount of maltodextrin exceeds about 10% by weight of the total mixture. However, it has been found that in order to provide a direct compression vehicle having a high carrying capacity, it is necessary to spray the admixture of the crystalline sugar and maltodextrin with an aqueous solution containing dissolved therein at least about 5% weight/volume of the maltodextrin.

As stated hereinabove, the amount of maltodextrin employed in the direct compression compositions of this invention is critical. The final composition will generally contain more than about 10% by weight of the maltodextrin which is introduced into the matrix of the crystalline sugar composition, either by the initial blending of the maltodextrin with the crystalline sugar and/or by the admixture treatment with the aqueous solution containing the maltodextrin which follows the blending of the crystalline sugar and the maltodextrin. Preferably, the tabletting composition will contain from about 15 to about 35% by weight of the maltodextrin based on the total amount of the direct compression vehicle. Particularly good results are obtained when the level of maltodextrin in the tabletting composition is in the range of from about 20 to about 30% by weight.

In one typical example of the above-described process of preparing the direct compression tabletting compositions of the present invention, a premix is formed by admixing 80 parts by weight of dextrose monohydrate crystals and 20 parts by weight of maltodextrin having a dextrose equivalent value in the range of from about 9 to about 13, the water content of the mixture being in the range of from about 2 to about 15% by weight. The mixture is thereafter thoroughly agitated and sprayed with an aqueous solution containing the aforesaid maltodextrin in an amount such that a damp mass is formed. The amount of maltodextrin dissolved in the aqueous solution is preferably 10 to about 40% weight/volume. In a typical example, 50 ml. of a 20% weight/volume aqueous solution containing the aforesaid maltodextrin is sprayed onto 1 kg. of the dextrose-maltodextrin admixture (800 grams of dextrose and 200 grams of maltodextrin). The sprayed mixture is thereafter dried to a moisture content of less than about 10%, preferably less than about 5% by weight. Alternatively, the granulated mixture may be wet screened through a number 6 sieve prior to drying to the desired moisture content. However, satisfactory results are obtained by drying the granulated mixture prior to screening.

The particle size of the direct compression tabletting composition of the present invention is rather important. Most pharmaceutical compounds have a particle size of less than 100 mesh. Accordingly, the carrier must be coarser or have a particle size larger than the pharmaceutical compound. If the particle size of the direct compression tabletting composition or vehicle is broadly dispersed, stratification will occur and uniform amounts of ingredients in the respective tablets will not be successfully accomplished. Therefore, it is important that the particle size of the direct compression tabletting compositions of the present invention have a relatively narrow particle size distribution. The particle size distribution found to be most desirable should be such that the particles of the composition fall within the range of -20 to about +200. However, better results are obtained wherein the composition has a particle size in the range of from about -30 to about +150 and, more preferably, in the range of from about -40 to about +100.

In the preferred preparation of pharmaceutical tablets by the present invention, an active material ingredient is thoroughly mixed by any suitable dry blending technique with the above-described direct compression tabletting composition in relative amounts required to provide a resultant superficially dry, free-flowing formulation directly compressible into tablets, and the formulation is then tabletted by direct compression.

Active ingredients contemplated to be employed in the preparation of tablets by the present invention constitute all active ingredients compatible with the above-described direct compression tabletting compositions. The present invention is particularly suitable for the use in preparing tablets containing the well-known pharmaceutically active materials. Specific examples of pharmaceutically active ingredients which advantageously may be tabletted by the present invention include ascorbic acid, sodium salicylate, acetaminophen, sodium bicarbonate, aluminum hydroxide, magnesium trisilicate, Vitamin E acetate, calcium lactate, ferrous sulfate and mixtures thereof.

Particularly preferred pharmaceutically active materials include ascorbic acid (Vitamin C), acetaminophen (APAP), aluminum hydroxide in combination with sodium bicarbonate (an antacid); citric acid in combination with sodium bicarbonate (an antacid), and magnesium trisilicate in combination with aluminum hydroxide (in a ratio of 2:1, respectively, as another antacid).

The pharmaceutically active materials may be present at relatively high levels in the tablets produced from the vehicles of the present invention. These tablets, even when they contain a high level of the active material, possess acceptable hardness and friability values, not possessed by other sugar-based tablets such as those described in British Pat. No. 1,286,275. The tablets of the present invention may be prepared by direct compression utilizing relatively small amounts of pressure in high speed tabletting machines. Due to the unusual structural integrity of the direct compression tabletting vehicles of the present invention, the vehicles may be simply dry mixed with the desired active materials, and, alternatively with conventional tabletting aids such as fillers, lubricants and the like, to obtain active ingredient-containing formulations which are directly compressible into tablets in conventional tabletting equipment. These directly compressed tablets exhibit the desired hardness and friability even though they are sugar-based compositions. The fact that the tablets are sugar-based and also contain the new relatively tasteless maltodextrins renders the tablets quite suitable for chewable type formulations. In other words, the sugar in the tablets masks the undesirable flavor of many active materials. Thus, the present invention provides pleasant tasting chewable tablets which may contain a high level of active material therein and still have the appropriate hardness and friability necessary for commercial manufacture and shipping of these tablets.

The novel tabletting vehicles of the present invention are also characterized as having properties which sat-
isfy the requirements of a binder for the active material and a disintegrant for the tablet in an aqueous medium. Thus, the compositions of the present invention are capable of being directly compressible into tablets having commercially acceptable hardness, friability and disintegration properties merely by blending the compositions of the present invention with an active material and compressing the mixture with conventional tabletting equipment.

The actual reason why the novel tabletting vehicles of the present invention are capable of carrying relatively high levels of active materials and still maintain commercially acceptable hardness, friability and disintegration properties when directly compressed at low pressures is not fully understood. These unusual properties are not as evident in the "agglomerated" dextrose-maltodextrin tabletting compositions described in British Pat. No. 1,286,275. Not wishing to be bound by any theory, it is believed, however, that the addition of the aqueous solution containing the maltodextrin dissolved therein to the uniform mixture of the crystalline sugar and maltodextrin achieves a form of granulation which provides a unique structural integrity in the vehicle. This structural integrity, it is believed, provides a matrix whereby the active material can be locked therein and the resulting composition thereby uniquely possesses a low elastic modulus, a high dislocation density and a high degree of plastic deformation. Since the vehicles of the invention are free-flowing, non-hygroscopic and compatible with active ingredients and common additives, as well as having fast disintegration properties, they are excellent direct compression vehicles.

The unique structural integrity of the direct compression vehicles of the invention which makes it possible for the granulated mixture of a crystalline sugar such as dextrose and from about 10% to about 50% by weight of a water soluble maltodextrin having a measurable dextrose equivalent value not substantially above about 20, wherein said granulated mixture contains less than about 10% by weight moisture, to be capable of being formed into hard, substantially non-friable tablets by direct compression when in admixture with up to 80% by weight of at least one pharmaceutically active ingredient, said tablets have a Strong Cobb Hardness Unit Value (S.C.H.U.) of about 6.0 or more, and are substantially non-friable.

In many instances, the tablets of the invention which contain the aforesaid active ingredients will have a hardness value greater than about 7 S.C.H.U. and quite often greater than about 9 S.C.H.U. The hardness values referred to herein are generally obtained by compressing the dry blended vehicle of the present invention with the active material at pressures as low as 2,000 pounds and, more consistently, such hardness values are obtained when the dry mix is compressed at pressures of 3,000 - 5,000 pounds (as is generally the case in some commercially available tabletting machines). The hardness and friability properties are further improved when the level of maltodextrin is increased to a value of from 15-35%, the most preferred levels being in the range of from about 20-30% by weight.

A preferred embodiment of the invention comprises a directly compressed pharmaceutical composition in tablet form, comprising a dry-blended mixture of up to about 80% by weight of a pharmaceutically active ingredient such as ascorbic acid or acetaminophen and at least about 20% by weight of a granulated mixture of dextrose and about 15 to about 35% by weight of a water soluble maltodextrin having a measurable dextrose equivalent value not substantially above about 20, said granulated mixture containing less than about 10% by weight moisture, said directly compressed pharmaceutical composition having a Strong Cobb Hardness Unit (S.C.H.U.) value of at least about 6. Typically, the preferred tablets of the invention will contain from about 15 to about 35% by weight of the pharmaceutically active ingredient. Of course, the level of active ingredient in the tablet having the desired hardness value will vary from one active ingredient to another. For example, higher levels of ascorbic acid can be tolerated as compared to Vitamin E acetate to attain the desired hardness values with the vehicles of the present invention at comparable pressures of preparation. In any event, it is quite unexpected that a crystalline sugar such as dextrose based vehicle is capable of providing substantially non-friable, hard tablets when directly compressed with high levels of active ingredients.

As mentioned hereinabove, various known additives such as lubricants, fillers, colors and disintegrants may be added to the novel vehicles of the present invention for their known purposes. Such additives include magnesium stearate, talc, Cæb-O-Sil, Cellutab, Sta-Rx 1500, Magnapal, etc. These additives may be present in amounts ranging from about 0.25% by weight to about 10% by weight or more. The amount of additive, such as the suitable lubricant, will generally depend on the active material employed, and the speed and pressure of the tabletting machine utilized.

Because of the plethora of terms that are in common use in the art, a few definitions are made to simplify the present application and permit it to be more concise. The terms "tablet hardness", "tablet friability", "weight variation", "tablet disintegration", and "accelerated stability study" are defined as follows:

**Tablet Hardness**
A measure of the strength of tablets (average of ten or more tablets) and their ability to retain their physical integrity, expressed in terms of Strong Cobb Hardness Units (S.C.H.U.), as determined by conventional procedure using the Strong Cobb Hardness tester of the Strong-Cobb-Arner Company, Cleveland, Ohio, and the average of these readings is reported herein as "mean hardness". The hardness tester was actuated by hand at 60±5 strokes per minute.

**Tablet Friability**
A measure of the tendency of tablets (average of 10 or more tablets) to crumble and dust, expressed in terms of percent weight loss, as determined by the "Roche" test described in the Journal of the American Pharmaceutical Association, Scientific Edition, Vol. 45, pages 114–116 (1956). This is conducted by sampling ten or more tablets from each batch by first de-dusting the tablets and weighing the same. The tablets are then subjected to the friability test in a Roche Friabilator at 20 revolutions per minute. The tablets are allowed to roll and fall for 4 minutes and thereafter de-dusted and weighed again. The loss of weight is reported as percent loss from the original weight. It is well-known that an active ingredient-containing tablet displaying a weight loss of less than about 1% generally is consid-
3,873,694

ered to have acceptable friability. Such a tablet character-
istic is herein defined as "substantially non-friable."

Weight Variation

This test is conducted by accurately weighing 10 or
more tablets from a batch on a Mettler Balance and the
high and low limits of the tablet weights are noted and
the mean of these two limits is taken.

Tablet Disintegration

The time observed for tablets (range of six tablets) to
disintegrate in water, as determined by a modification,
in which the use of this is eliminated, of the procedure
for uncoated tablets described in Pharmacopoeia of the
(1960).

The pressure-hardness profiles were obtained from
different dextrose products and Royal-T ("agglomer-
ated") mixture of dextrose monohydrate wet filter cake
and about 5% by weight Mor-Rex Code 1918) on a
Carver Press. This test was strictly comparative.

Prior to the experiment, the die faces and punch faces
of the Carver Press, which was utilized to measure the
pressure-hardness profiles, were swabbed with 5%
solution of stearic acid in chloroform and allowed
to dry. One-half gram of the test material was placed in
the die and compressed on the Carver Press at various
pressures, maintaining a constant dwell time of 10 sec-
onds in all cases. The compressed tablet was ejected
from the die by pushing out with the upper punch and
its hardness (breaking strength) was determined on the
Strong Cobb Hardness tester. Five tablets were com-
pressed at each pressure level, and their average hard-
ness value determined. Table 1 indicates the pressure-
hardness values of dextrose monohydrate, dehydrated
dextrose, anhydrous dextrose and Royal-T.

The above data are indicative that all of the dextrose
exhibit poor compressibility and, therefore, they are
not suitable as direct compression vehicles. The Royal-
T product without any active ingredient exhibited a sat-
sactory compressibility profile.

EXAMPLE 2

Evaluation of Mixtures of Various Ratios of Dextrose
Monohydrate and Maltodextrin Prepared by Different
Methods, on Carver Press

a. Dry Blends of Dextrose Monohydrate and
Maltodextrin:

Four 1 kilogram batches of a dry blend of dextrose
monohydrate and a maltodextrin (Mor-Rex Code
1918) were prepared in ratios of 95/5, 80/20, 65/35
and 50/50, respectively, in a Hobart Bowl Mixer. Each
of the blends was mixed for 7 minutes, and subjected
to a pressure-hardness profile evaluation on a Carver
Press. The results are set forth in Table 2.

11

12

15

20

25

30

35

40

45

50

55

60

TABLE 1
Pressure-Hardness Comparison Expressed in S.C.H.U.

<table>
<thead>
<tr>
<th>HARDNESS VALUE IN S.C.H.U. AT:</th>
<th>1000 lbs.</th>
<th>2000 lbs.</th>
<th>4000 lbs.</th>
<th>6000 lbs.</th>
<th>8000 lbs.</th>
<th>10,000 lbs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUBSTANCE TESTED</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular Dextrose (dextrose monohydrate)</td>
<td>N.T. **</td>
<td>0.75</td>
<td>6.5</td>
<td>9.5</td>
<td>3.0</td>
<td>2.0</td>
</tr>
<tr>
<td>Dehydrated Dextrose</td>
<td>N.T.</td>
<td>4.2</td>
<td>6.0</td>
<td>0.0</td>
<td>N.T.</td>
<td>N.T.</td>
</tr>
<tr>
<td>Anhydrous Dextrose</td>
<td>N.T.</td>
<td>Did not form tablets.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royal-T</td>
<td>N.T.</td>
<td>9.4</td>
<td>21.6</td>
<td>B.S.</td>
<td>B.S.</td>
<td>B.S.</td>
</tr>
</tbody>
</table>

**N.T. = Not Tested
* B.S. = Beyond Scale

TABLE 2

<p>| BLEND |</p>
<table>
<thead>
<tr>
<th>Dextrose Monohydrate % by Wt.</th>
<th>Maltodextrin % by Wt.</th>
<th>HARDNESS VALUE IN S.C.H.U. AT:</th>
<th>2000 lbs.</th>
<th>4000 lbs.</th>
<th>6000 lbs.</th>
<th>8000 lbs.</th>
<th>10,000 lbs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>95</td>
<td>5</td>
<td>4.5</td>
<td>14.4</td>
<td>23.8</td>
<td>B.S.</td>
<td>B.S.</td>
<td>B.S.</td>
</tr>
<tr>
<td>80</td>
<td>20</td>
<td>6.4</td>
<td>22.4</td>
<td>B.S.</td>
<td>B.S.</td>
<td>B.S.</td>
<td>B.S.</td>
</tr>
<tr>
<td>65</td>
<td>35</td>
<td>5.2</td>
<td>25.4</td>
<td>B.S.</td>
<td>B.S.</td>
<td>B.S.</td>
<td>B.S.</td>
</tr>
<tr>
<td>50</td>
<td>50</td>
<td>5.6</td>
<td>27.4</td>
<td>B.S.</td>
<td>B.S.</td>
<td>B.S.</td>
<td>B.S.</td>
</tr>
</tbody>
</table>
Based upon the data in Table 2, it is quite evident that dry blends of a crystalline sugar such as dextrose and a maltodextrin would not be suitable as a vehicle for carrying high levels of a pharmaceutically active ingredient, since hardness values of the mixture about 2,000 pounds are generally less than 6.

b. Dextrose Monohydrate Granulated with Aqueous Solutions Containing a Maltodextrin:

Five 1 kilogram batches of dextrose monohydrate were each granulated with 30 ml. of a solution containing 5, 10, 20, 30 and 40% W/V of a maltodextrin (Mor-Rex Code 1918, a waxy starch hydrolysate having a D.E. of about 9-13 which readily dissolves in water in concentrations of up to 40% W/V). The granulation was accomplished by slowly adding the maltodextrin solution to the dextrose to obtain a damp mass. The damp mass was thoroughly mixed in a Hobart Bowl Mixer. The damp mass was screen through a No. 6 sieve and dried in an oven to a final moisture content of 8.2 to 8.8%. The moisture content was determined on an Ohaus Moisture Determination Balance. The heating element was set at a point corresponding to 100°C, and the timer was set for 60 minutes. The loss in weight was noted every 15 minutes until there was no further loss. The percentage moisture lost was read off the scale directly. All the granulations were dry screened to obtain a particle size such that 100% passed through a No. 16 screen and 49% passed through a No. 80 screen. (The “screening” described herein and throughout this paper was conducted on a Sytron test sieve shaker, Model TSS25B, manufactured by the Sytron Company, Homer City, Pa., and U.S. Standard Sieves (A.S.T.M. specifications), manufactured by Fisher Scientific Company, New York, New York.) All the granulations were subjected to the pressure-hardness profile evaluation on the Carver Press. The details of the amounts of the solvents used in each batch and the results of the pressure-hardness profile are set forth in Table 3.

The data in Table 3 clearly indicate that simple granulation of a crystalline sugar such as dextrose with an aqueous solution containing a maltodextrin does not provide a tableting composition having commercially acceptable hardness values at the commercially utilized pressures of 2,000 pounds.

EXAMPLE 3

Granulation of Dextrose Monohydrate-Maltodextrin Mixture with Aqueous Solutions Containing Maltodextrin

This experiment illustrates the granulation of various levels of a mixture of dextrose monohydrate and maltodextrin with various solutions containing maltodextrin dissolved therein. A calculated quantity of dextrose monohydrate was screened through a No. 20 sieve (to remove any lumps) and mixed with varying amounts of maltodextrin (Mor-Rex Code 1918) in a Hobart Bowl Mixer for 5-7 minutes. The weight of the mixture in each batch was 1 kilogram. To each mixture there was added 50 ml. of a solution containing dissolved therein the maltodextrin (Mor-Rex Code 1918) to obtain a damp mass. The damp mass was mixed an additional 7 minutes following the addition of the maltodextrin solution to cause granulation, whereupon the granulated damp mass was wet screened through a No. 6 sieve and dried in an oven to a final moisture content of 8.2 to 8.6%. The dried, granulated products were evaluated on a Carver Press to ascertain their ability to form commercially acceptable tablets. The details of the preparation and the results of the hardness profile evaluation are set forth in Table 4.
EXAMPLE 4
Evaluation of Compressibility and Carrying Capacity of Dextrose-Maltodextrin Granulated Direct Compression Vehicles

In this experiment, the compressibility and carrying capacity of the dextrose-maltodextrin granulated direct compression vehicle was evaluated. The granulated vehicle used herein was prepared in the same manner described in Example 3 by admixing 80% by weight of dextrose monohydrate with 20% by weight of the maltodextrin (Mor-Rex Grade 1918, a waxy starch hydrolsate having a D.E. of 9-13) and thereafter granulating the admixture with a 20% W/V aqueous solution of the maltodextrin (50 ml. of solution per 1,000 grams of dextrose monohydrate and maltodextrin admixture). The particle size of the direct compression vehicles utilized in this experiment was such that they passed through a No. 20 sieve.

The vehicles with and without the active ingredient were formed into tablets in a Stokes Model B-2, 16 station rotary tablet machine which had been set up with four ¾ inch s.c. toolsing and a standard feed frame to enable gravity feed. All samples of the granulation were first inspected for physical appearance. In each instance, 0.5% concentration of magnesium stearate was used as a tablet lubricant. The tablets were prepared at the maximum load obtainable, which was determined by gradually increasing the press pressure until a distinct knocking sound caused by a pressure overload was heard, and then easing off on the pressure until the knocking sound ceased. The hardness values for tablets produced at maximum pressure were obtained and recorded. The operating press pressure was then reduced to produce tablets with hardness values approximately one-third of the maximum and two-thirds of the maximum readings. In this manner, tablets were obtained with three different hardness values, ranging from one-third to maximum hardness for each material evaluated. The tablets were evaluated for weight variation, hardness, friability, disintegration and stability. The die fill in all cases was adjusted so as to produce tablets weighing 0.5 gram. The flow of the base from the hopper to the dies under operating conditions was observed and noted.

Each of the active ingredients (ascorbic acid granular), as supplied by Hoffman-LaRoche Inc. and acetaminophen (APAP), special power, supplied by S. B. Penick & Co.) were mixed with the granulated direct compression vehicle in a proportion of 50-50% in a Hobart Bowl Mixer for 5-7 minutes. Then, 0.5% to 0.75% by weight of magnesium stearate was mixed with the vehicle and active ingredient as a lubricant. The mixture was then fed into the tablet press, described above in this Example. In the event that tablets were not formed with a given mixture of active ingredients and granulated direct compression vehicle, the ratio was altered to increase the amount of vehicle while lowering the level of the active ingredient. This procedure was followed until the ratio which produced acceptable tablets under identical operating conditions was produced.

"Acceptable" tablets are defined as those which possess minimum friability, effective hardness and rapid disintegration time. Samples of tablets produced at different pressures were taken and subjected to tests for hardness, weight variation, friability, disintegration and stability. The details of these experiments and their results are tabulated in Table 5.

In each instance, the granulated direct compression composition was indicated as having excellent compressibility characteristics and carrying capacity. The granulated direct compression composition exhibited excellent flow from the hopper to the dies of the tablet press. However, the flow properties of the APAP compositions were not quite as good as the ascorbic acid containing compositions. The weight variation of the tablets was also excellent.

The tablets prepared hereinabove were also subjected to an Accelerated Stability Study, wherein the tablets from each batch were packed in a wide-mouth bottle, which was tightly stoppered and stored in a trypotype drier at 50°C ± 2°C, for 7 days. The tablets were then removed and subjected to tests for hardness, disintegration and friability. Any change in physical appearance was also noted. The comparative results of the Accelerated Stability Study are set forth in Table 6.
Table 6

| FORMULATION | ACCELERATED STABILITY STUDY
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>% Active Ascorbic Acid</td>
<td>% Lubricant Magnesium Stearate</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>30</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>25</td>
</tr>
</tbody>
</table>

**Storage at 50°C for 7 days.**

**Ascorbic acid granular.**

**APAP (special powder, S. B. Penick & Co.).**

A = Acceptable

The results tabulated in Table 6 clearly reveal that the granulated direct compression vehicles of the invention provide excellent tablets. The Accelerated Stability Studies indicate that there is a substantial increase in tablet hardness with a noticeable decrease in friability and no change in the disintegration time of the tablets. All of the tablets had an excellent white appearance.

**EXAMPLE 5**

In this experiment, the flowability, compressibility, and carrying capacity of granulations of different particle sizes are compared.

In each of the tests, the vehicle was prepared by the granulation process of Example 3, wherein 80% by weight of dextrose monohydrate was admixed with 20% by weight of the maltodextrin (Mor-Rex Code 1918, a waxy starch hydrolysate having a D.E. of 9-13) and thereafter the admixture was granulated with a 20% W/V aqueous solution of the maltodextrin (50 ml. of the solution per 1,000 grams of dextrose monohydrate and maltodextrin admixture). Each of the granulations tested was passed through a Fitz Mill using a suitable screen (No. 2A or No. 1) with knives forward at medium speed. The comminuted granulations were then hand sieved so as to obtain three particle size ranges, viz.: -20 +60, -40 +100, and -100 +200. The granulations (except the controls which did not contain active ingredient) were dry blended with sodium bicarbonate, aluminum hydroxide gel, dried; magnesium trisilicate, dried; (all three supplied by Rugar Chemical Co., New York), acetaminophen (APAP) regular powder, (as supplied by S. B. Penick & Co.) as indicated in Table 7. Each of the samples tested contained a lubricant. The mixtures of the vehicle and the active ingredient were placed in a Colton Model No. 204, 4 Station Rotary tablet machine which had been set up with 8% inch S.C. tooling and a standard feed frame to enable gravity feed. The die fill in all cases was adjusted so as to produce tablets weighing 0.5 gram. The flow of the base from the hopper to the dies under operating conditions was observed and noted. Also, each of the mixtures and resulting tablets was inspected for physical appearance. The tablets were prepared at three different pressure levels as described hereinabove. The results of the tests are summarized in Table 7 hereinafter.

**Table 7**

<table>
<thead>
<tr>
<th>DETAILS OF EXPERIMENTS ON CAPACITIES OF DIFFERENT PARTICLE SIZE RANGES OF GRANULATED VEHICLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Granulation (particle size range)</strong></td>
</tr>
<tr>
<td>(sodium Bicarbonate</td>
</tr>
<tr>
<td>-20 +60</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>-40 +100</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>-100 +200</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

The evidence set forth in Table 7 demonstrate that all three particle size ranges of -20 +60, -40 +100 and -100 +200 have excellent compressibility characteristics. In general, the -40 +100 particle size range carried the maximum amount of actives. At the pressures utilized in the experiments, sodium bicarbonate was carried by all three particle size ranges at the maximum level, while APAP was carried the least. The flowability of the granulations alone or in admixture with the active was good to excellent for all formulations. The weight variation (U.S.P.) test was also good to excel-
lent. However, the –20 +60 and –40 +100 particle size ranges illustrated the best uniformity.

**EXAMPLE 7**

This experiment compares the vehicles of the present invention alone or in combination with various actives served. Although no significant role was attributed in the tablets having less than 10% by weight moisture, it is desirable to keep the moisture content as low as possible from the standpoint of stability of the active medicinal ingredient (e.g., some actives are moisture sensitive).

**TABLE 8**

<table>
<thead>
<tr>
<th>Granulated Vehicle % Moisture Content</th>
<th>% ACTIVE</th>
<th>% LUBRICANT</th>
<th>EVALUATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Bicarbonate</td>
<td>APAP</td>
<td>Magnesium Tristate</td>
<td>Aluminum Hydroxide Gel, Dried</td>
</tr>
<tr>
<td>8.2 (± 0.2%)</td>
<td>35</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>15</td>
<td>–</td>
<td>–</td>
<td>1.25</td>
</tr>
<tr>
<td>25</td>
<td>2.0</td>
<td>1.0</td>
<td>7.0</td>
</tr>
<tr>
<td>7.5</td>
<td>92</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>4.2 (± 0.2%)</td>
<td>35</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>15</td>
<td>–</td>
<td>–</td>
<td>1.25</td>
</tr>
<tr>
<td>25</td>
<td>2.0</td>
<td>1.0</td>
<td>8.2</td>
</tr>
<tr>
<td>Slight</td>
<td>6.5</td>
<td>79</td>
<td>0.11</td>
</tr>
<tr>
<td>8.2</td>
<td>89</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>2.2 (± 0.2%)</td>
<td>35</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>15</td>
<td>–</td>
<td>–</td>
<td>1.25</td>
</tr>
<tr>
<td>25</td>
<td>2.0</td>
<td>1.0</td>
<td>8.7</td>
</tr>
<tr>
<td>7.0</td>
<td>82</td>
<td>0.15</td>
<td></td>
</tr>
<tr>
<td>8.0</td>
<td>93</td>
<td>0.13</td>
<td></td>
</tr>
</tbody>
</table>

at various moisture content levels.

The vehicle used in this experiment was prepared in the same manner as previously described in Examples 3–6. The vehicle was a granulated admixture of 80% by weight of dextrose monohydrate and 20% by weight of the maltodextrin granulated with a 20% W/V solution of a maltodextrin. The final granulated admixture was screened to a particle size range of –40 +100. The granulation was dried in an oven at different temperatures and for different lengths of time so as to obtain at least three different moisture content levels, 8.0, 4.0 and 2.0%, by weight. The tablets were prepared on a Colton Model No. 204, 4 station rotary tablet machine in the same manner described in the previous examples. The tablets were evaluated for weight variation, hardness, friability and disintegration. All four active medicinal ingredients (described in Table 8) which had been dry blended with the vehicle of the invention were selected to evaluate the capacities of the granulations in the same manner previously described. The details of the experiment are set forth in Table 8.

As it can be seen from the data in Table 8, there was no significant difference in the compressibility and carrying capacity of the granulation at higher and lower moisture content levels. The tablets made from the granulations with lower moisture content were checked for capping and capping of the tablets was not ob-

**EXAMPLE 8**

This experiment was performed to evaluate the carrying capacities of the granulations of the present invention with additional active medicinal agents.

Each of the active ingredients (ascorbic acid (type S); calcium salicylate; ferrous sulfate (excitated); and Vitamin E acetate; 50% S.D.) were mixed with the granulated vehicle of Example 3 and tested in exactly the same way as described in Example 4. Each of the blended mixtures of granulated vehicle and active medicinal ingredient had excellent flow characteristics from the hopper to the tablet die. The tablets also had a very narrow weight variation. All of the active ingredients were carried very well and the resulting tablets were of extremely high quality, having a friability of less than 2%. Sodium salicylate was carried the least and it required a larger amount (2%) of lubricant. Vitamin E acetate (1:1) was carried up to 55%. The addition of 0.25% Cab-O-Sil as a glidant was extremely helpful in aiding the flow characteristics of the blend from the hopper to the tablet die. Calcium lactate and ferrous sulfate, excitated, were carried up to 35% and had excellent hardness and friability characteristics.

Ascorbic acid (type S) at the 20% level produced excellent tablets having less than 1% friability and a hardness value of about 6. The details of the experiments and results are tabulated in Table 9.

**TABLE 9**

<table>
<thead>
<tr>
<th>FORMULATION</th>
<th>Active Medicinal Agent</th>
<th>Active Carried By Granulated Vehicle</th>
<th>% LUBRICANT</th>
<th>EVALUATION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Magnesium Stearate</td>
<td>Talc</td>
<td>Cab-O-Sil</td>
</tr>
<tr>
<td>Ascorbic Acid¹</td>
<td>20</td>
<td>0.5</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vitamin E Acetate² (50% S.D.)</td>
<td>55</td>
<td>0.5</td>
<td>–</td>
<td>0.25</td>
</tr>
</tbody>
</table>
TABLE 9—Continued

DETAILS OF EXPERIMENTS ON CARRYING CAPACITIES OF GRANULATED VEHICLE WITH ACTIVE MEDICINAL INGREDIENTS

<table>
<thead>
<tr>
<th>FORMULATION</th>
<th>Active Carried By Granulated Vehicle</th>
<th>% LUBRICANT</th>
<th>EVALUATION</th>
<th>Hardness In S.C.H.U.</th>
<th>Disintegration in Min.</th>
<th>% Friability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active Medicinal Agent</td>
<td></td>
<td>Magnesium Stearate</td>
<td>Talc</td>
<td>Cab-O-Sil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium Lactate</td>
<td>35</td>
<td>1.0</td>
<td></td>
<td></td>
<td>12.5</td>
<td>12.0</td>
</tr>
<tr>
<td>Ferrous Sulfate, Exciplex</td>
<td>30</td>
<td>0.5</td>
<td></td>
<td></td>
<td>7.6</td>
<td>25</td>
</tr>
<tr>
<td>Sodium Salicylate</td>
<td>10</td>
<td>2.0</td>
<td></td>
<td></td>
<td>5.0</td>
<td>23</td>
</tr>
</tbody>
</table>

1 Ascorbic Acid (type S), Hoffman-La Roche, New Jersey.
2 Vitamin E Acetate (50% S.D.), Hoffman-La Roche, New Jersey.

EXAMPLE 9

This experiment was performed to determine the effect of Sta-Rx 1500 (available from A. E. Staley Mfg. Co., Decatur, Ill.) on the disintegration time of the tablets of the granulations per se, as well as in combination with various active medicinal agents.

The same granulated vehicle used in the previous Example 3 was employed, which was an admixture of 80% by weight dextrose monohydrate and 20% of the water soluble maltodextrin granulated with a 20% W/V solution of the maltodextrin. The dried granulated vehicle was screened to obtain a mesh size in the range of 40 +100. The screened granulated vehicle (except the control) was blended with Sta-Rx 1500 to obtain 10% by weight of Sta-Rx of the total mixture. The Sta-Rx 1500 was also added to the formulations containing the active medicinal ingredients, displacing the granulated direct compression vehicle. The tablets were prepared in the same manner as described in Example 4, keeping the hardness the same as the tablets without Sta-Rx 1500.

The tablets were evaluated for weight variation, hardness, friability and disintegration. The addition of the directly compressible starch, Sta-Rx 1500, did not effect the carrying capacity of the granulated vehicle of the invention. However, very slight capping was observed in the case of the calcium lactate formulation. This result was expected, since tablets containing starches have a tendency to cap. There was a decrease in disintegration time for the tablets containing Sta-Rx 1500, as compared to those tablets without it. The reduction of time was about one-third of the original time. The flow from the hopper to the tablet die for all samples was excellent. The friability in all of the experiments measured less than 1%. All of the tablets had good hardness values. The hardness value for Vitamin E acetate tablets ranged from 3.8 to 4.0, simply because of the reference pressure for the control tablets to produce a hardness value of 10.8. The hardness value of these tablets could be increased to about 6 or more by simply increasing the pressure used to form the tablets. The tablets nevertheless had an excellent physical appearance.

The details of the experiment and results thereof are set forth in Table 10.

TABLE 10

EFFECT OF STA-RX 1500 AS A DISINTEGRANT ON GRANULATED VEHICLE WITH AND WITHOUT ACTIVE MEDICINAL INGREDIENTS

<table>
<thead>
<tr>
<th>FORMULATION</th>
<th>% ACTIVE</th>
<th>% LUBRICANT</th>
<th>EVALUATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin E Acetate (50% S.D.)</td>
<td>Calcium Lactate</td>
<td>Magnesium Stearate</td>
<td>Talc</td>
</tr>
<tr>
<td>—</td>
<td>—</td>
<td>0.75</td>
<td>—</td>
</tr>
<tr>
<td>—</td>
<td>—</td>
<td>0.75</td>
<td>—</td>
</tr>
<tr>
<td>55</td>
<td>—</td>
<td>0.5</td>
<td>—</td>
</tr>
<tr>
<td>55</td>
<td>—</td>
<td>1.0</td>
<td>—</td>
</tr>
<tr>
<td>—</td>
<td>35</td>
<td>1.0</td>
<td>—</td>
</tr>
</tbody>
</table>

EXAMPLE 10

This experiment was conducted to evaluate the rate of moisture pick-up by the granulations of the present invention per se, and in combination with active medicinal agents at a given relative humidity to ascertain the stability of the active medicinal agents with the granulated vehicle and the performance of the formulations containing the granulated vehicle under industrial working conditions, where a whole batch runs for eight hours or more, when moisture pick-up is possible.

The experiment was performed using the same granulated vehicle used in the previous Examples which had been prepared by admixing 80% by weight of dextrose monohydrate with 20% by weight of the maltodextrin, and thereafter granulating the admixture with a 20% W/V aqueous solution of the maltodextrin (50 ml. of solution per 1,000 grams of dextrose monohydrate and maltodextrin admixture). Vitamin C and Vitamin E acetate were blended with several samples to provide 20 and 55% by weight of the active medicinal agent in the total blend, respectively. The rate of moisture pick-up of the granulated vehicle, per se, and in combination
3,873,694

With the active medicinal agents was studied at 50%, 70 and 90% relative humidity at room temperature.

The moisture pick-up of the samples tested was determined using the below-described procedure.

The Rosano Surface Tensiometer, Model: LG, manufactured by the Federal Pacific Electric Company, N.J., was employed in conjunction with Scheibler Desiccators, containing constant relative humidity solutions. One gram of the test material which was placed in an aluminum pan (supported by a wire ring) was hooked onto the Surface Tensiometer with a thread passing through a 2-inch length of rubber tubing partly slipped over a 3-inch length of plastic tubing. The glass tubing was fitted into the tubublate of the desiccator top through a one-hole rubber stopper. The test material, the aluminum pan with the ring, the nylon thread were counterbalanced by necessary weights to produce a tensiometer reading of 0.00 mg. Readings were taken at the end of each hour and the increase in weight was noted.

All of the samples exhibited very little moisture pick-up. The samples subjected to 50% relative humidity exhibited a maximum moisture pick-up after 4–5 hours of less than 2.8%, by weight (increase in weight attributed to moisture pick-up). The samples subjected to 70% relative humidity exhibited a maximum moisture pick-up after about 5 hours of less than 6%, by weight. The samples subjected to 90% relative humidity exhibited a maximum moisture pick-up after 11 hours of less than 20%, by weight. Based upon the results of the above moisture pick-up tests, it is apparent that the granulated vehicles, per se, or in combination with the active medicinal agents are not troubled by moisture pick-up when exposed to relative humidities of less than about 75%. This desired result is quite unexpected in light of the propensity of dextrose containing compounds to be hygroscopic, i.e., they tend to pick-up moisture upon standing.

**EXAMPLE 1**

This experiment demonstrates the excellent density and fluff characteristics possessed by the granulated vehicles of the present invention, which characteristics enable the vehicle to have the good flow properties from the hopper to the tablet die. As it is well-known, the tablet thickness actually depends on the volume occupied by the vehicle in the die cavity. Tablet thickness is related to the density of the granulation as volume and is inversely proportional to the density. Thus, the denser the granulation, the less volume will be occupied at a given weight, producing thinner tablets. The thickness of the tablets determines the choice of a given packaging unit and even the toolings to be used in their manufacturing. This Example determines the fluff and top densities of the granulations; first, the weight of the material at a given volume, and secondly, the volume is evaluated at a given weight of material. In each test, the granulated vehicle was prepared as previously described in Example 3, using 80% by weight of dextrose monohydrate and 20% by weight of the maltodextrin.

The details of the procedure employed to determine the fluff density and top density of the granulated vehicle of the invention are as follows:

**Fluff Density**

Each granulated vehicle sample was poured down a gentle slope into a tarred 10-ml cylinder. The weight of the material contained in this volume was noted, and was reported as "Fluff Density" in grams/ml.

**Top Density**

Each granulated vehicle sample (50 grams) was accurately weighed and transferred to a 100-ml cylinder. The cylinder was gently tapped on a thick layer of cloth, until no further perceptible decrease in volume was observed. The weight of the granulations was divided by the volume obtained, and the result was reported as "Top Density" in grams/ml.

The results of the tests revealed that the granulated vehicle tested had a Fluff Density of 0.65 gram/ml and a Top Density of 0.71 gram/ml. These values are indicative of excellent characteristics of the granulated vehicles of the present invention.

**EXAMPLE 12**

Several granulated vehicles were prepared utilizing the unique procedure described in Example 3, except that in place of Mor-Rex Code 1918, an acid hydrolysate having a D.E. of about 15 (Frodex, available from American Maize-Products), an enzyme hydrolysate having a E.E. of about 5 (Mor-Rex P908), and two dextrins (Globe Dextrin and Excello Dextrin, available from CPC International Inc.) were employed in amounts of 10, 20 and 30% by weight in the initial blend with the dextrose monohydrate. The respective maltodextrin or dextrin was placed in water and the solution or dispersion (containing 20% W/V of the maltodextrin or dextrin) was used to granulate the blend. The blend were dried to a moisture content of 3–5% and screened of oversize granules above a No. 14 mesh. Each of the granulated vehicles was mixed with 1.0% magnesium stearate for lubrication and was formed into tablets on a Model F single stroke tableting machine set at a ratio of 45 strokes per minute and at 1/16 tons of pressure.

In all instances, the granulated vehicles were free-flowing and had acceptable compressibilities. Slight scoring of tablets was observed in the vehicles prepared from the acid hydrolysate (Frodex) and Mor-Rex P908, therefore, necessitating a higher amount of lubricant or inclusion of an anti-adherent. From a hardness and friability standpoint, all blends made acceptable tablets. All of the granulated vehicles demonstrated very little hygroscopcity at 50, 70 and 90% relative humidity. The acid hydrolysate (Frodex) containing vehicles. However, the acid hydrolysate containing vehicles were slightly more hygroscopic than the other vehicles tested. The dextrin containing vehicles, while they provided suitable tablets, were not acceptable because the tablets possessed a yellow color and had a burnt flavor. Thus, it is necessary to employ the maltodextrins to product commercially acceptable granulated vehicles for use in the pharmaceutical industry.

As it can be seen from the foregoing evidence, the present invention has now provided a unique granulated vehicle having an unusual structural integrity and density. The structural integrity and density of the granulated vehicles provides a tableting composition having excellent flowability and capability of forming strong, hard and substantially non-friable tablets, even when the tablet contains up to about 80% by weight of the tablet, a pharmaceutically active material. By referring to a substantially non-friable tablet, it is meant a
tablet which loses less than about 1% by weight, as determined by the "Roche" test described hereinabove. While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modification, and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and as may be applied to the essential features hereinafore set forth, and as fall within the scope of the invention.

1. A method for producing a direct compression vehicle for tabletting comprising:
   a. admixing a crystalline sugar with from about 10 to about 50% by weight, based upon the weight of said vehicle, of a maltodextrin having a measurable dextrose equivalent value not substantially above about 20 to form a uniform admixture,
   b. concurrently agitation and spraying said admixture with an aqueous solution containing dissolved therein a maltodextrin having a measurable dextrose equivalent value not substantially above about 20, said aqueous solution of dissolved maltodextrin being present in an amount sufficient to provide a damp mass of said uniform admixture and to cause granulation of said uniform admixture, and
   c. drying said granulated uniform admixture to a moisture content of less than about 10% by weight, based upon the weight of said vehicle.

2. The process of claim 1, wherein said crystalline sugar is dextrose.

3. The process of claim 2, wherein the dextrose is a centrifuge cake containing up to about 16% by weight moisture, based upon the weight of the centrifuge cake.

4. The process of claim 1, wherein said crystalline sugar is admixed with from about 15 to about 35% by weight of said maltodextrin, based upon the weight of said vehicle.

5. The process of claim 1, wherein said aqueous solution contains from about 5 to about 40% weight/volume solution of said maltodextrin.

6. The process of claim 1, wherein said maltodextrin is a waxy starch hydrolysate having a dextrose equivalent value in the range of from about 9 to about 13 and a descriptive ratio of at least about 2, said descriptive ratio being the sum of the percentages (dry basis) of saccharides of the maltodextrin with a degree of polymerization of 1 to 6 divided by the dextrose equivalent value.

7. A method for producing a direct compression vehicle for tabletting comprising:
   a. admixing a crystalline dextrose having a moisture content of up to about 16% by weight with from about 15 to about 35% by weight, based upon the weight of said vehicle, of a maltodextrin having a measurable dextrose equivalent value not substantially above about 20 to form a uniform admixture,
   b. concurrently agitation and spraying said uniform admixture with an aqueous solution containing dissolved therein from about 10% to about 40% weight/volume of a maltodextrin having a measurable dextrose equivalent value not substantially above about 20, said aqueous solution of dissolved maltodextrin being present in an amount sufficient to provide a damp mass of said uniform admixture, c. agitating said sprayed uniform admixture to uniformly intermingle said crystalline dextrose and maltodextrin with said aqueous solution to cause granulation of said admixture, and
   d. drying said granulated uniform admixture to a moisture content of less than about 10% by weight.

8. The method of claim 7, wherein the crystalline dextrose is admixed with from about 20 to about 30% by weight, based upon the weight of said vehicle, of said maltodextrin.

9. A directly compressible tabletting vehicle comprising a granulated mixture of a crystalline sugar and from about 10 to about 50% by weight, based upon the weight of said vehicle, of a water soluble maltodextrin having a measurable dextrose equivalent value not substantially above about 20, said granulated mixture containing less than about 10% by weight moisture, based upon the weight of said vehicle, said directly compressible tabletting vehicle in admixture with up to about 80% by weight, based upon the weight of said vehicle, of at least one pharmaceutically active ingredient, being characterized as capable of being formed by direct compression at a pressure as low as about 2000 pounds into hard, substantially non-friable tablets having a Strong Cobb Hardness Unit (S.C.H.U.) value of at least about 6.

10. The directly compressible tabletting vehicle of claim 9, wherein said crystalline sugar is dextrose.

11. The directly compressible vehicle of claim 9, wherein said water soluble maltodextrin is present in an amount ranging from about 15 to about 35% by weight, based upon the weight of said vehicle.

12. The directly compressible vehicle of claim 9, wherein the moisture content of said vehicle is less than about 5% by weight, based upon the weight of said vehicle.

13. A method for preparing tablets comprising forming an admixture of the product of claim 9 and an active material, said product comprising at least about 20% by weight of said vehicle, and compressing the mixture into tablets.

14. A method for preparing tablets comprising forming an admixture of the product of claim 10 and an active material, said product comprising at least 20% of said vehicle, and compressing the mixture into tablets.

15. The method of claim 14, wherein said active material is a pharmaceutically active material.

16. The method of claim 15, wherein said pharmaceutically active material is a member selected from the group consisting of ascorbic acid, sodium salicylate, acetasaminophen, sodium bicarbonate, aluminum hydroxide, magnesium trisilicate, Vitamin E acetate, calcium lactate, ferrous sulfate and mixtures thereof.

17. A directly compressed pharmaceutical composition in tablet form, comprising a dry-blended mixture comprising:
   a. at least one pharmaceutically active ingredient present in an amount up to about 80% by weight, based upon the weight of said directly compressed pharmaceutical composition; and
   b. a directly compressible vehicle comprising a granulated mixture of a crystalline sugar and at least about 10% by weight, based upon the weight of the directly compressible vehicle, of a water soluble maltodextrin having a measurable dextrose equiva-
lent value not substantially above about 20, said directly compressible vehicle containing less than about 10% by weight moisture, said directly compressible vehicle being present in an amount of at least about 20% by weight, based upon the weight of said directly compressed pharmaceutical composition, said directly compressed pharmaceutical composition being characterized as being hard and substantially non-friable, and being further characterized as having a Strong Cobb Hardness Unit (S.C.H.U.) value of at least about 6.

18. The directly compressed pharmaceutical composition of claim 17, wherein said crystalline sugar is dextrose.

19. The directly compressed pharmaceutical composition of claim 17, wherein said directly compressible vehicle comprises a granulated mixture of dextrose monohydrate granulated with 15 to about 35% by weight, based upon the weight of the vehicle, of a maltodextrin having a measurable dextrose equivalent value not substantially above about 20.

20. The directly compressed pharmaceutical composition of claim 17, wherein said pharmaceutically active ingredient is a member selected from the group consisting of ascorbic acid, sodium salicylate, acetaminophen, sodium bicarbonate, aluminum hydroxide, magnesium trisilicate, Vitamin E acetate, calcium lactate, ferrous sulfate and mixtures thereof.

21. The directly compressed pharmaceutical composition of claim 17, which additionally includes a small but effective amount of materials selected from the group consisting of lubricants, coloring aids, disintegrants, binders and mixtures thereof.

22. A directly compressed pharmaceutical composition in tablet form, comprising a dry-blended mixture comprising:

a. ascorbic acid in an amount of up to about 80% by weight, based upon the weight of said pharmaceuti-

cal composition; and

b. a directly compressible vehicle comprising a granulated mixture of dextrose and about 15% to about 35% by weight, based upon the weight of said vehicle, of water soluble maltodextrin having a measurable dextrose equivalent value not substantially above about 20, said vehicle containing less than about 10% by weight moisture.

said directly compressed pharmaceutical tablet being characterized as being hard and substantially non-friable such that the tablet has a Strong Cobb Hardness Unit (S.C.H.U.) value of at least about 6.

23. The composition in accordance with claim 22, wherein said composition contains ascorbic acid in an amount from about 15 to about 35% by weight, based upon the weight of the tablet.

24. A directly compressible tabletting vehicle comprising a granulated mixture of dextrose and from about 15 to about 35% by weight, based upon the weight of the vehicle, of a water soluble maltodextrin having a measurable dextrose equivalent value not substantially above about 20, said granulated mixture containing less than about 5% by weight moisture, based upon the weight of said vehicle, said directly compressible tabletting vehicle in admixture with at least one pharmaceutically active ingredient in an amount of from about 15 to about 35% by weight, based upon the weight of the total composition, being characterized as capable of being formed by direct compression at a pressure as low as 2000 pounds into hard, substantially non-friable tablets having a Strong Cobb Hardness Unit (S.C.H.U.) value of at least about 6, said vehicle being further characterized as having a particle size in the range of from about -40 to about +100 mesh screen.

25. The directly compressible tabletting vehicle of claim 24, wherein said vehicle additionally contains a tabletting lubricant.